Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-06

Clinical Trial Update: Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PK/PD, safety and tolerability of LIK066 in patients with decreased renal function has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LIK066 (LIK066)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Impairment | Phase 2 | Status: COMPLETED | Results posted: 2019-02-06